Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Product Availability Update

Promega Manufacturing and Delivery Systems continue to be fully operational during the COVID-19 outbreak. Our teams are in regular contact with suppliers and distributors worldwide and are taking all steps necessary to address both demands for diagnostic tools and reliable delivery of all products as quickly as possible. Learn more

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Use of ADCC Reporter Bioassays in Influenza Vaccine Development

Topics covered in this Webinar include:

  • Development of a stable trimeric influenza HA stem as a broadly protective immunogent
  • The role of ADCC as an important bnAb MOA
  • Application of a novel ADCC reporter bioassay to assess bnAb MOA
  • Best practices in ADCC reporter bioassay setup, optimization and application

Summary

Increasing evidence suggests that antibody-dependent cellular cytotoxicity (ADCC) plays a significant role in antibody-mediated protection and control of viral infection.  For influenza in particular, it is becoming increasingly clear that an important in vivo effector function of broadly neutralizing antibodies (bnAbs) includes Fc receptor-mediated ADCC.

This webinar will highlight the development of a novel influenza vaccine that induces bnAbs targeting the HA stem and the role of ADCC in protective immunity. 
Dr. Kuipers will also discuss the application of the Promega ADCC reporter bioassays in influenza vaccine development with special emphasis on the setup and use and of a murine FcγRIV version of the assay.


Speaker

harmjan-kuipers-phd-126x125

Harmjan Kuipers, PhD
Senior Scientist
Janssen Pharmaceuticals, Belgium

Harmjan Kuipers did his PhD in immunology in the lab of prof. Lambrecht in Rotterdam, The Netherlands focusing on dendritic cell based immunotherapy in murine models of asthma. He then moved for a 2-year postdoc project to the lab of prof. Brocker in Munich, studying mircoRNAs in dendritic cell development and function. In 2008 he started to work at Crucell, now part of Janssen Vaccines, where is he is currently involved in the development of a universal influenza vaccine.

We love to talk science.

Sign up to receive monthly invitations to our webinars.

Sign Up